NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Archean Chemical Industries, GlaxoSmithKline Pharma, MakeMyTrip and Nexus Select Trust are in focus after ICICI Securities reiterated positive views on the four companies following their June-quarter updates, highlighting strong growth levers ranging from specialty chemicals and pharmaceuticals to travel technology and retail real estate.
Among the key ideas, MakeMyTrip remains one of ICICI Securities' preferred picks in the internet space. The brokerage maintained its Buy rating with a target price of $74, citing market-share gains in higher-margin non-air segments, resilient travel demand and continued investments in artificial intelligence.
ICICI Securities retained its Add rating on GSK Pharma and raised its target price to Rs 2,900 from Rs 2,725, citing a strong launch pipeline that includes Blenrep and Arexvy, along with expectations of sustained double-digit revenue growth.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
